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Abstract:
Klebsiella pneumoniae is a Gram-negative bacterium responsible for nosocomial
infections such as blood stream infections, meningitis, and septicemia. Clinical isolates confirm
K. pneumoniae is increasingly antibiotic resistant (AR) making treatment more difficult. While
bacterial exposure to antimicrobial substances is a known cause of the AR phenotype, there still
exists gaps in knowledge about the genetic changes responsible for this fitness change. The
laboratory Klebsiella pneumoniae 43816 (ATCC 43816) was exposed to sublethal concentrations
of Cephalothin for a 14-day period. At the end of the experimental treatment, the adapted
population acquired clinical antibiotic resistance along with phenotypic and morphological
changes. The goal of this study is to identify and characterize genetic mutations which correlate to
increases in antibiotic resistance and morphological changes in the adapted K. pneumoniae
population. DNA was extracted and sequenced from the adapted bacteria and a population
subcultured for 14 days without exposure to antibiotic. Comparison of these sequences to the
known ATCC 43816 genome identified eight mutations unique to the adapted culture in seven
protein coding regions. Results also found 6 putative promoter regions with mutations in the
adapted culture. The data confirm that fixed changes in genotype are correlated with the altered
phenotype. Additionally, findings suggest that the development of resistance may involve genes
not previously known for β-lactamase function in Klebsiella pneumoniae and that the exact
mechanism used to overcome antibiotic exposure is not uniform within a treated population.
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Chapter 1: Introduction
Microbial Resistance to Antibiotics
Since the development of antibiotic treatment, bacterial pathogens have been competitively
evolving in ways that allow them to survive antibiotic pressure (1–3). Acquisition of the antibiotic
resistant (AR) phenotype can occur genetically in two primary ways- through random mutations
in the existing bacterial genome and through acceptance and integration of foreign genetic material
encoding AR traits. Both methods have caused the current global resistance crisis, but it is the fact
that microorganisms mutate in the presence of low concentrations of antibiotic medication that
creates difficulty (1, 2). Pathogenic infections which were initially considered mundane in the
antibiotic heyday, have reemerged as consistent threats as they become increasingly difficult to
treat. Antibiotic resistant forms of common infections is costing the US approximately $5 billion
as of 2016 with the cost expected to rise (1). Another assessment in 2020 found that these
pathogens are causing over 2 million infections per year and 23,000 deaths (4). A special class of
commonly resistant bacteria have gained notoriety as ESKAPE pathogens. The members of this
group- Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa, and Enterobacter species- are known for their knack at
“escaping” the effects of antimicrobial substances (2, 4, 5).
The misuse and abuse of medications by medical staff, patients, and even the agricultural
industry has created a basal level of antibiotic in our environment (6–9). Interestingly, the residual
antibiotic concentration isn’t high enough to completely eradicate bacterial populations, but it does
become a source of survival stress. In proper clinical settings, antibiotics are administered such
that the concentration in the affected area reaches a limit referred to as the Minimum Inhibitory
Concentration or MIC (10, 11). The MIC of an antibiotic is the concentration at which a bacteria
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fails to grow and is dependent upon the compound being tested and the bacteria itself (10, 11). At
that level, a normally functioning immune system would be able to clear a pathogen (10).
Concentrations below that bacteriostatic limit, referred to as sub-MIC levels, are similar to what
has become known as the “selection window” for bacteria (12, 13). An antibiotic concentration
within a selection window is high enough to stress a population by killing some bacterial cells but
low enough to not completely eradicate that population. It is the concentration at which the
occurrence of genomic mutations is highest and can lead to the development of clinical antibiotic
resistance in available pathogens (12, 13). Interestingly, the environmentally available antibiotic
doesn’t always have to be the exact same as those used by clinicians to create resistance to
medically prescribed agents. Exposure to chemicals like the surface antiseptic chlorhexidine, and
veterinary antibiotics timicosin and florfenicol can create cross-resistance in human pathogens to
different classes of medicinal treatments (7, 9).
Resistance Mechanisms Specific to β-Lactam Antibiotics
β-lactam antibiotics are a commonly used treatment by clinicians for a wide range of
infectious bacteria. As one of the three largest classes of antibiotics, they have been used to combat
bacterial infections for over 60 years (14, 15). β-lactams are antibiotics that disrupt peptidoglycan
bonds in the cell walls of Gram-positive and Gram-negative bacteria (16). The ring structure within
the antibiotic compounds simulates the D-Ala-Ala substrate used by bacterial enzymes involved
in forming and linking the peptidoglycan layer of the cell wall (14). Disabling the penicillinbinding proteins, or PBPs, necessary to link this cell wall component creates instability. The
eventual disruption of the cell wall triggers lysis and clearing of the infection in susceptible
organisms. β-lactam antibiotics were initially effective against a host of both Gram-positive and
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Gram-negative species since they are potent inhibitors of cell-wall synthesis- a process essential
for bacterial proliferation (14, 15).
Gram-negative bacteria like K. pneumoniae have three methods to overcome the
destructive action of this class of antibiotic. The first method involves the enzymatic destruction
of β-lactam rings in the antibiotic to prevent their binding with penicillin-binding proteins or PBPs
(17). This method deactivates the antibiotic and allows the bacteria to continue synthesizing
peptidoglycan for cell wall synthesis. A second pathway to mitigate β-lactam induced lysis is to
alter the conformation or collection of penicillin-binding proteins produced by the bacteria (17).
Changing PBP conformation or changing the types of PBPs available reduces the likelihood that
β-lactams will bind to these proteins and prevent inhibition of cell wall synthesis. Finally, Gramnegative organisms can decrease uptake of the antibiotic by changing the abundance and
characteristics of porins (17). Without access into the cell, the antibiotic will not have the
opportunity to deactivate necessary PBPs.
Strains of K. pneumoniae have been identified utilizing all three of these mechanisms. For
example, both nosocomial and hypervirulent strains of the species have modified capsule
composition and quantity, the external lipopolysaccharide layer, efflux pumps and porins to
prevent or reduce the admittance of antibiotic into the intracellular space (3). Isolates of K.
pneumoniae with β-lactamase and extended-spectrum β-lactamase (ESBL) genes code for
enzymes able to hydrolyze multiple classes of the antibiotic, even the strongest group named
carbapenems, rendering them ineffective (14, 15). The bacteria are also known to readily accept
plasmids from other species which encode modified PBP enzymes (14, 18). The alterations modify
enzyme binding sites such that accessibility for the antibiotic is drastically reduced or obliterated.
These adaptations have landed K. pneumoniae on a clinical “hot list” of sorts. Medical personnel

4

and government agencies recognize the rapid rise in resistance among this and other bacteria as
costly and eventually detrimental to human health (6, 19).
Laboratory Models of Microbial Adaptation to Antibiotics
Gullberg et. al. (2011) attempted to further understand the selection window hypothesis
proposed by Drlicka in 2003 using wild-type S. typhimurium and E. coli species (20). These
organisms were exposed to varying levels of antibiotic prior to a growth competition assay with a
counterpart of the same species which was not exposed to antibiotics. The team utilized
streptomycin, tetracycline, and ciprofloxacin for antibiotic exposure and competed each strain pair
for 80 generations. Regardless of the antibiotic or species there existed a concentration at which
the pre-exposed strain’s growth was enriched compared to the unexposed bacteria. In Figure 1, a
graphical model and equation of comparative fitness rates at sub-MIC antibiotic concentrations
and beyond is shown (20). The minimum concentration needed to create this fitness change varied
by antibiotic type. Furthermore, the experiment questioned if sub-MIC concentrations of antibiotic
could not only affect the ability of the bacteria to survive in the presence of antibiotic but if this
could create a resistance phenotype. To do this susceptible bacterial populations were grown in the
presence of streptomycin for 700 generations. Moderate resistance to the MIC concentration of
antibiotic was observed after 200-400 generations and high resistance within 500-600 generations
(20). Their findings are an example of how even low levels of antibiotics, like those found in
human tissues after antibiotic use or in agricultural products/land used, can create competitive
circumstances that could drive the rise in AR occurrence in bacteria.
Since that experiment, exposure to low concentrations of antibiotics have been linked to
changes in resistance phenotypes and genes. In a study using the ESKAPE pathogen P. aeruginosa,
samples were exposed to sub-MIC concentrations of either ticarcillin or carbenicillin, both β-
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lactam antibiotics which inhibit peptidoglycan synthesis (8). The samples were initially exposed
on an antibiotic inoculated plate and selected colonies were transferred to broth for resistance
analysis. It is important to note that the study measured mutation rate by the ability of the samples
to later grow on plates inoculated with rifampicin. It was determined that both ticarcillin and
carbenicillin treatments increased the relative proportions of AR colonies compared to the
unexposed original strain (8). Later, carbapenem-resistant K. pneumoniae (KPC) samples were
examined for carbohydrate use and transcription rate changes when exposed to imipenem (21). All
the KPC samples used were resistant to imipenem and had known carbapenemase genes at the
onset of the trial. Samples grown in the presence of imipenem before the assays preferentially used
different carbohydrate metabolites and differentially expressed RNA compared to untreated
samples. Most notably the exposed samples upregulated RNA transcripts of genes related to
transmembrane transport and hydrocarbon transport/metabolism while downregulating genes
involved in translation, ribosome structure, and cell division (21). In contrast, clinical isolates of
P. aeruginosa showed a lower mutation rate in the glpT gene compared to a common lab strain of
the species after in vitro exposure to ciprofloxacin (22). However the same study noted six
nonsynonymous mutations in the coding regions of known antibiotic-adaptable genes (22).
While these studies have expanded on our body of knowledge concerning sub-MIC
exposure and bacterial adaptation there are some key missing pieces. First, these experiments
began with strains of bacteria either known to harbor antibiotic resistance genes or shown to be
clinically resistant to one form of antibiotic already. Another area for concern is the brief exposure
time used before many of these assays. In most cases, the samples were exposed to the sub-MIC
concentration of the antibiotic for 24-48 hours before experimentation began. This allowed limited
time for the bacteria to evolve a novel genetic change as it may occur in a hospital or environmental
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setting with consistent and extended term exposure. Finally, the genetic analyses, if completed,
used pre-determined targets or the phenotypes assumed from mutations in predetermined targets
(i.e. mutagenesis calculated by growth in rifampicin, mutation rate determined by glpT and
fosfomycin resistance, sequencing only known antibiotic adaptable genes). The results are
definitely informative but not as transferrable to situations in which AR phenotypes evolve over
time though sub-lethal exposure.
Klebsiella pneumoniae Pathology and Genome
K. pneumoniae is an ESKAPE pathogen which is not only able to survive in the presence
of multiple classes of antibiotics, including resistance to last-resort level medications such as βlactams and the subclass of carbapenems, but also acquires resistance at a faster rate than many
other bacteria in this family (3, 23, 24). According to the 2015 National Action Plan For Combating
Antibiotic Resistant Bacteria, resistant K. pneumoniae was responsible for over 7,000 patient
infections (6). Similar infection rates have been noted globally with many antibiotic-resistant
strains of Klebsiella species exhibiting resistance to all classes of antibiotics used by medical
professionals (3).
In 2015, genome sequencing of over 300 Klebsiella pneumoniae isolates confirmed the
existence of three subspecies (previously referred to as three phylogroups or serotypes: KPI, KPII,
and KPIII) of K. pneumoniae that independently evolved mechanisms of resistance and
pathogenicity (18). Klebsiella pneumoniae 43816 belongs to the KPII subspecies, a phylogroup
which was almost exclusively isolated from human hosts. The KPII group was also closely
associated with instances of colonization or hospital acquired infection (18). Sequencing of those
isolates identified as K. pneumoniae indicated the presence of β-lactamase genes in chromosomal
regions and in plasmids, which confirmed the evolution of resistance in a bacterial population
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through the work of horizontal gene transfer. However, finding resistance genes in chromosomal
regions suggests involvement of viral-mediated gene transfer or the bacteria’s ability to adapt over
time. While the distribution of antimicrobial resistance genes and specific combinations varied by
region, isolates from humans on average contained a median of five antimicrobial resistance genes
(18). Thus, Klebsiella pneumoniae 43816 as a member of the KPII serotype would also share this
ability and potentially contain multiple antibiotic resistance genes.
The data obtained in my work uses an adapted strain of ATCC 43816 and will focus on
chromosomal genes as opposed to plasmid sequence data. The laboratory strain ATCC 43816 was
treated for 14 days with gradually increasing concentrations of cephalothin, a β-lactam class
antibiotic (Figure 2). While the concentration of antibiotic administered increased, it never reached
the level clinically issued for treatment of infection. Clinical cephalothin concentrations can range
from 90-400 µg/mL but only 90% of the dosage is bioavailable when administered and is degraded
and cleared by the body within 4-6 hours (25). Therefore, the effective clinical dosage ranges from
9-40 µg/mL. As a control, a sample of K. pneumoniae 43816 was also serially passaged for 14
days with similar environmental conditions save for exposure to antibiotics. Both treatments were
subcultured every 12 hours, and the concentration of cephalothin for K. pneumoniae exposed to
antibiotic was increased by 0.5 µg/mL every 24 hours. The concentration of antibiotic in the treated
condition increased from an initial 0.5 µg/mL to 7.5 µg/mL by the end of the adaptation period.
At the end of the 14-day treatment, the sample exposed to cephalothin successfully grew
in the presence of antibiotic whereas the unexposed sample had minimal growth in the same
conditions. Cephalothin treatment slowed the growth rate for the adapted population compared to
the untreated form, as indicated by the reduced slope in growth curve (0.028 OD units per minute
treated, 0.034 OD units per minute untreated) during the exponential phase in Figure 3.
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Additionally, the treated and untreated populations exited lag phase sooner than K. pneumoniae
43816 (Figure 3). Even though it had never been exposed to clinical doses, this adapted variant
exhibited resistance to clinical doses and greater of cephalothin. The antibiotic tolerance was
quantified using the minimum concentration of antibiotic required to reduce bacterial growth by
90%. This breakpoint MIC increased in the adapted K. pneumoniae population from 4 µg/mL to
125 µg/mL while the sample not exposed to antibiotic still displayed expected phenotypic
susceptibility (Table 1). This value is more than triple the concentration necessary to inhibit growth
of standard ATCC 43816. When the two cultures were examined, the adapted strain showed a
visibly more mucoid phenotype (Figure 4) and was comprised of a small colony producing variant
and a large colony producing variant (Figure 5). When plated each size variant reliably produces
clones that are in the same size range as the parent colony. Small colony variants also appear more
filamentous and are more likely to cluster in chains (Figure 6). While still resistant to clinical levels
of cephalothin use, the small colony producing variant is less resistant to Cephalothin treatment
than the large colony clones (Table 2).
The present study will focus on a laboratory strain of K. pneumoniae which has evolved
resistance to the β-lactam antibiotic cephalothin through exposure to incrementally increased, sublethal antibiotic dosage levels as described above. The primary goal of this study was to identify
and characterize genetic changes in the adapted strain associated with increased antibiotic
resistance. Additionally, the small and large-colony variant sequences were compared to identify
mutations shared between the two groups which could be an effect of antibiotic exposure. Notable
genetic changes could provide insight into the evolutionary pathway of multidrug resistance and
provide new targets for therapeutic research.
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Chapter 2: Methods
Bacterial Strains and Media
An experimentally treated population of Klebsiella pneumoniae was generated to model
the acquisition of antibiotic resistance through low-concentration antibiotic exposure. The design
utilized Klebsiella pneumoniae ATCC 43816 (ATCC, Manassas, VA) and all incubation steps
were completed at 37°C with shaking at 180 rpm. As shown in Figure 2, two 50-µL aliquots of
K. pneumoniae 43816 grown in Luria-Bertani (LB) broth (BD Difco, Franklin Lakes, NJ) were
dispersed into fresh culture tubes and stressed with a concentration of one μg/mL cephalothin
(Fisher Scientific, Waltham, MA) then grown until the cultures reached an OD600 of 1.0 read by
an Eppendorf Bio photometer (Hamburg, Germany). Four 50 μL aliquots of bacteria from this
treatment were subcultured in fresh broth with two samples inoculated by one μg/mL of
cephalothin and two samples unexposed to antibiotic. Aliquots from all four populations were
subcultured in fresh broth every 12 hours. The cephalothin concentration for the exposed
population of K. pneumoniae, referred to as “treated” or “adapted”, increased by 0.5 μg/mL with
each subculture over the course of 14 days. The cephalothin concentration ultimately reached 7.5
µg/mL by the end of the exposure cycle (Figure 2). Samples from each day of treatment were
aliquoted to make frozen stock for further use in minimum inhibitory concentration and qPCR
assays.
For use in further assays in the project, untreated bacteria samples were grown from the
saved frozen stock in LB broth and incubated for 12-18 hours at 37°C at 180 rpm. The treated
bacteria samples were also grown from frozen stock in similar conditions with the addition of 7.5
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μg/mL cephalothin treatment to maintain the final antibiotic stress to which the population had
acclimated.
Growth
Growth curves were generated for both the treated and untreated experimental groups and
the parental bacterial strain to assess changes in growth rates over time. Growth curves were
generated by inoculating five milliliters of Luria Bertani broth (supplemented with antibiotics
when appropriate) with five microliters of overnight culture to determine the effect of
cephalothin-exposure on K. pneumoniae growth rates. The OD600 was determined using an
Eppendorf Bio photometer every 30 minutes for five hours.
Genomic DNA Isolation
Genomic DNA from both experimental populations and the parental strain were used for
sequence analysis to identify potential mutations compared to the published sequence data for K.
pneumoniae 43816. DNA extraction steps mirrored those published by Wright et. al. with
modifications (26). The procedure utilized 50 mL of overnight culture (inoculated with the
appropriate amount of antibiotic) and pelleted by centrifugation for 10 minutes at 10,000 rpm at
4°C. The pellet collected was washed twice with 30 mL of TE25S buffer (25 mM Tris-HCl, 25
mM EDTA, 0.3 M sucrose, pH 8.0). After washing the pellet was resuspended in 25 mL of
TE25S with 10 mg/mL lysozyme and 15 μL RNAse (ThermoFisher Scientific, Waltham, MA).
The mixture was incubated for one to two hours at 37°C while shaking at 150 rpm. Then 300 µL
of proteinase K (ThermoFisher Scientific, Waltham, MA) and 1.5 mL of 10% SDS
(ThermoFisher Scientific, Waltham, MA) were added and incorporated by inversion. The sample
was then incubated for 1-2 hours at 50-55°C with 3 inversions in the incubation period. After
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incubation, 5 mL of 5M NaCl were added and incorporated by inversion followed by 3.25 mL of
CTAB(Cetyl Trimethyl Ammonium Bromide)/NaCl. The solution was again mixed by inversion
and incubated at 55°C for 10 minutes. The sample was then split into two 50mL Falcon tubes
and 20mL of a 24:1 chloroform/isoamyl alcohol solution was added to each tube. The samples
were incubated at room temperature and 100 rpm for 20 minutes. After incubation, the solution
was centrifuged at 4°C and 10,000 rpm for 15 minutes and the upper aqueous layers were
transferred into fresh tubes. The chloroform treatment was repeated a second time. The upper
aqueous layers of both samples were isolated and combined. An isopropyl alcohol volume of 0.6
of the collected sample was added and the mixture was gently inverted. This solution incubated
for five minutes and the DNA was spooled from the tube onto a sterile Pasteur pipette. The
spooled DNA was washed with approximately 5 mL of 70% ethanol and dried before being
suspended in 300µL of EB buffer (QIAGEN, Hilden, Germany).
Genome Sequencing
Initial samples of DNA from the K. pneumoniae 43816, the 14-day treated population,
and 14-day untreated population were analyzed by the National Center for Genome Resources
for SMRT Cell Sequencing. The samples were compared against the published reference
sequence NZ_CP009208.1 available in GenBank. Genetic variation between genomes was
calculated using a modified form of FST or analysis of variance referred to as ϴ (27). FST values
are evaluated against the null hypothesis that the populations are not genetically unique (27).
Pacific Biosciences calculated allele frequencies and utilized a proprietary Quiver Algorithm to
maximize accuracy in sequence reads using variation between the published genome and prior
records.
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A secondary round of sequencing detailed the complete sequence of samples from days
1-14 of the adaptation experiment, the small colony forming variant, the large colony forming
variant, and the day 14 adapted strain of K. pneumoniae. These DNA samples were analyzed by
the Microbial Genome Sequencing Center which utilized an Illumina sequencing technique
similar to that used by Baym et. al. (28). Any variations were analyzed using a proprietary breseq
variant calling algorithm (29).
Minimum Inhibitory Concentration Test
Survivability of both experimental groups and the parental strain in the presence of an
antibiotic was assessed using a Minimum Inhibitory Concentration (MIC) assay. Standard K.
pneumoniae 43816 and samples from each day of experimentation were grown in five mL of LB
at 37°C at 180 rpm overnight. Overnight cultures were then diluted to reach 103 CFUs/mL in LB
broth in a 96 well microtiter plate. Bacteria were treated with 500, 250, 125, 62.5, 31.25, 16, 8, 4,
2, 1, and .5 μg/mL of the tested antibiotic: cephalothin, amikacin, or tetracycline (Fisher
Scientific, Waltham, MA). Amikacin and Tetracycline were tested due to mutations in genes
known to confer resistance in related bacterial species. Wells containing only LB and bacteria
were used as controls for normal growth. The absorbance of each well at OD600 was measured
using a Biotek Gen5 plate reader (Winooski, VT). The minimum inhibitory concentration was
determined as the lowest concentration at which growth was significantly inhibited (by at least
90%).
Transcriptional Expression by qPCR
The initial sequence data for the experimental groups identified mutations in coding and
potential promoter regions unique to the 14-day treated population. To better understand how
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these mutations impacted protein production, the transcription rates for those genes in the 14-day
treated population were compared to that of the parental population using qPCR. The QIAGEN
RNeasy kit (Hilden, Germany) was used to extract RNA from cultures in the exponential phase
with a DNase and lysozyme treatment. Complimentary DNA (cDNA) was reverse transcribed
from 1μg of total RNA using random hexamer primer and the Superscript III reverse
transcriptase kit (ThermoFisher Scientific, Waltham, MA). Quantitative polymerase chain
reaction (qPCR) was performed using the New England Biolabs Luna Universal qPCR kit
(Ipswich, MA) on an Eppendorf Mastercycler Realplex 2 (Hamburg, Germany). Data was
analyzed using the ΔΔCT method (30). Gene expression was normalized to that of gapA and the
adapted strain was normalized to the lab strain 43816. Primers used are listed in Table 3.
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Chapter 3: Results
Exposure to Cephalothin Alters K. pneumoniae Phenotype and Colony Morphology
At the end of the 14-day experiment there were several morphological differences
between the treated and untreated groups. The present study found that the adapted population of
K. pneumoniae exhibited increased mucoidy in liquid culture compared to the clonally related
untreated group (Figure 4). While the viscosity had changed, the adapted population did not
qualify as a hypermucoviscous (hmv) strain as indicated by a string test.
Upon plating the untreated group produced uniform colonies of the same size as the K.
pneumoniae 43816 progenitor. When the adapted population was streaked onto an LB agar plate,
two disparate colony morphologies were observed (Figure 5). The plates consistently contained a
mixture of larger colonies and smaller colonies which were denoted as “treated large” and
“treated small”. Isolation and replating of one colony type produced a plate with uniform
colonies of the initial isolate’s size. An isolated large colony sample when propagated in liquid
culture and streaked would produce a plate of large colonies and an isolated small colony sample
would produce a plate of small colonies. The fact that colony size was maintained after isolation
indicated that the morphological change was heritable. A closer look at the small and large
colony variants revealed that the small colony forming bacteria were more filamentous in
structure and prone to linking with a neighboring individual bacterium (Figure 6).
Cephalothin Treatment Increases Minimum Inhibitory Concentration in a Stepwise
Manner and Induces Cross Drug Resistance
A minimum inhibitory concentration assay was used to determine the survival of
bacterial populations in various antibiotics. This study primarily highlighted the breakpoint
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concentration of antibiotic necessary to depress bacterial growth by half, also called the MIC50,
since in a clinical setting this strength would allow an individual’s immune system to clear an
infection. The original Klebsiella pneumoniae 43816 strain demonstrated 50% less growth
(MIC50) in a cephalothin concentration of 4 µg/mL (Table 1). After the 14-day treatment period,
the untreated population of bacteria maintained the same MIC50 and susceptibility to
cephalothin. However, the MIC50 for the adapted strain increased to 125 µg/mL (p<0.0005
compared to parental strain). Genome sequence data (see below) indicated mutations in genes
implicated in resistance to antibiotic substances with methods of action not akin to β-lactams
namely tetracyclines and aminoglycosides. Tetracycline and amikacin were used to check for
potential cross-resistance in all bacterial populations. The MIC50 recordings for Klebsiella
pneumoniae 43816 were 0.5 µg/mL for both antibiotics. The 14-day treatment moderately
affected the resistance to amikacin with an untreated population MIC50 of 1 µg/mL and 2 µg/mL
(p<0.05 and p<0.0005 compared to parental strain) for the adapted population. The subcultured
populations were more resistant to tetracycline. The untreated population had a doubled MIC50
of 1 µg/mL and the adapted population’s MIC50 increased to 16 µg/mL ((p<0.0005 compared to
parental strain).
Our study was also able to map changes in resistance through the adaptation period.
Samples from each subcultured day were analyzed by a MIC assay. Figure 7 shows that the
adapted strain demonstrated two clear jumps in resistance to cephalothin on day 6 (MIC50 of
31.25 µg/mL) and day 10 (MIC50 of 125 µg/mL) of treatment with periods of stability inbetween. Similarly, resistance to tetracycline occurred in two jumps, one on day 2 and the next
on day 5.
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Whole Group Genome Sequence Analysis of Adapted and Susceptible Populations
DNA from the untreated and adapted population of K. pneumoniae 43816 was sequenced
by the National Center for Genome Resources using a SMRT Cell methodology. The initial
sequence data identified 107 mutations in the control culture and 29 mutations in the genome of
the resistant culture. Of the 29 mutations identified in the adapted strain, 15 were
nonsynonymous changes that occurred in protein-coding regions of the sequence. To further
refine the list of potential targets, any mutations shared with the untreated population of bacteria
were removed. Comparing the two genomes highlighted seven protein coding genes which were
altered in the resistant sample DNA and none were identified as common β-lactamase genes
(Table 4A).
Table 4 lists mutations of protein coding genes first. The coding region mutations
included two nucleotide substitutions in an SGNH/GDSL hydrolase family protein, and a
substitution in undecaprenyl-phosphate glucose phosphotransferase. There were deletions in the
coding regions for N-acetyltransferase, a sugar ABC transporter ATP binding protein, and DNA
recombination protein RmuC. Finally, an insert in the globin coding sequence and a large insert
in a TetR/AcrR transcriptional regulator were noted. The only mutations identified in this set that
had not fixed in the population (mutations not found in 100% of the sample provided) were those
in the SGNH hydrolase coding region. The functions of these genes ranged from signal
transduction, energy and metabolite use, capsule formation, and nucleic acid proofreading.
Revisiting the sequence data revealed six unique mutations in potential promoter regions
of the adapted population sequence (Table 4B). The list was refined using a similar process as
that for the coding region calls. This study considered that promoter regions could occur
approximately 150 bp away from the gene of interest, so in reviewing the sequence data any
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mutations within 150 bp of a coding region was considered a potential promoter. While the genes
associated with these promoters are not fully characterized in Klebsiella pneumoniae, there are
data about each class of gene represented.
This analysis found mutations in potential promoters for SGNH/GDSL hydrolase, peptide
chain release factor 3, a LysR family transcriptional regulator, a type II asparaginase,
deoxyribopyrimidine photo-lyase, and cyclic di-GMP phosphodiesterase. The mutation for the
SGNH hydrolase promoter was again not fixed and only found in 56% of the sample. All the
remaining mutations were ubiquitous. Functions of the coding regions nearby included
metabolite use, signal transduction, and mRNA proofreading.
Genome Sequencing by Treatment Day Aligns Adapted Population Mutations and
Increases in Antibiotic Tolerance
Frozen stocks were made of the adapted K. pneumoniae 43816 population on each day of
treatment during the evolution experiment. DNA from each day was extracted and sequenced by
the Microbial Genome Sequencing Center (MiGS). MiGS identifies polymorphisms using an
Illumina sequencing method and a proprietary statistical algorithm for variant calling. The data
received for each day identified far fewer mutations than the first round of sequencing (Table
5A). To standardize the new sequencing data, the 14-day adapted population DNA was
sequenced by MiGS as well. Ultimately, four mutations in protein-coding regions were identified
using this method (Table 5A). The MiGS report did not include sequence polymorphisms in
noncoding regions, such as possible promoters, so that analysis could not be done.
Similar to the initial polymorphism data for the adapted strain, the TetR/AcrR
transcriptional regulator and wcaJ, an undecaprenyl phosphate glucose phosphotransferase, had
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an altered sequence compared to that available in GenBank for K. pneumoniae 43816 (Table 5).
The positions of the mutations are not identical but the type of mutation (insertion and base
change from T to G) align with the prior data. The mutation in the TetR/AcrR regulator sequence
reaches fixation on day 6 and is a consistently fixed mutation in each sample day afterward. The
mutation in wcaJ first fixes on day 10, and then the reported percentage of sample with this
mutation decreases for the following treatment days to 64% by day 14. Two new marginal
mutations were identified in the MiGS data- one affecting the rpoB gene and the other affecting
the gndA gene.
When the DNA sequences are compared for each daily sample, the data show when
certain mutations have cemented in the adapted population. One of the earliest mutations fixed in
the 14-day treated population on day 1 of treatment was that of rpoB. This occurs one day before
the first increase in resistance to tetracycline. On day 6 the TetR/AcrR family transcriptional
protein mutation moves from a low-frequency marginal call to a fixed mutation with 100%
coverage in the adapted strain (Figure 8). On day 10 the same occurs with the wcaJ sequence
which later decreases in frequency (Figure 8). These two fixation events align with the two MIC
jumps for the adapted strain indicating increased resistance to cephalothin (Figure 8).
Transcription of Mutated Genes
Quantitative real-time PCR indicated that extended antibiotic exposure affected the
relative transcription of some genes with mutated promotor or coding regions. Figure 9 displays
the relative transcription rates of genes with mutated coding regions identified in the first round
of sequencing. In that assay, transcription of the TetR/AcrR transcriptional regulator was
upregulated almost threefold in the adapted population of bacteria while that of globin was
downregulated almost fivefold when compared to the parental K. pneumoniae 43816 (Figure 9).
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Figure 10 shows the evaluated transcription rate of genes near potential promoters identified in
the first round of sequencing. The only promotor mutation which correlated with a statistically
significant change in nearby gene transcription was the deoxyribopyrimidine photolyase (Figure
10). The associated gene showed a nearly fourfold reduction in transcription (Figure 10).
Adapted Population Large and Small Colony Variant Sequencing Exposes Genetic
Subpopulations in Evolved Group
Inconsistencies in polymorphism coverage in the initial round of sequencing data along
with observations of colony size variance and difficulty in qPCR analysis supported the
possibility that the adapted population may consist of distinct subpopulations. To test this idea,
the large and small colony variants of the 14-day adapted population were separated and their
genome sequenced by the Microbial Genome Sequencing Center. The data indicated that the two
variants were genetically distinct and may even be comprised of subpopulations themselves
(Table 5B and 5C).
Both the large and small colony variants had mutations in the rpoB and TetR/AcrR
transcriptional regulator sequences (Table 5B and 5C). The mutation in rpoB was fixed in both
variants. However, the depth of coverage of the TetR/AcrR transcriptional regulator in the large
colony variant was 52 (Table 5B). Not all of this sample group developed a mutation to this gene
while the same change in the small colony variant had been fixed at 100% coverage.
The large colony variant also had a distinguishing marginal mutation call in a ComEC
family protein that was not found in the small colony variant. While the small colony data show
a large deletion between the wcaJ and gndA genes along with a single nucleotide polymorphism
in a YfiR family protein that was not identified in the large colony variant (Table 5C). All of the
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mutations in the small colony forming variant were fixed indicating a more homogenous
genomic identity than the large-colony forming subpopulation.
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Chapter 4: Discussion
An improved understanding of how bacterial pathogens develop antibiotic resistance in
response to exposure during growth can improve our ability to prevent and treat resistant forms
in a variety of settings. This study attempts to model the process of adaptive evolution by serially
subculturing one population of bacteria while gradually increasing cephalothin concentration
with each passage. Unlike other evolutionary studies using known resistant strains of bacteria or
antibiotic exposure for a shorter period of time, the adapted K. pneumoniae population was
stressed for a period of 14 days using a subMIC concentration of antibiotic and compared to a
clonally related cohort which was also serially passaged for the same amount of time without
antibiotic exposure.
Phenotypic Changes and Clinical Impact
This model produced a population with distinct characteristics from the parent species,
Klebsiella pneumoniae 43816. β-lactam antibiotics function by interrupting the generation and
repair of the cell wall for actively growing and dividing cells. Survival in the presence of such an
agent could affect the populations appearance and growth patterns. At the end of the treatment
period, the adapted population increased in mucoidy and contained distinct cell and colony
morphologies (Figure 4 and 5). The adapted population’s survivability in cephalothin was
expected to increase, however the shift in MIC from 4 µg/mL to 125 µg/mL illustrated that
bacterial survival improved exponentially (Table 1). Over the 14-day period, the adapted K.
pneumoniae developed the ability to survive in a concentration of cephalothin both above that
which is used clinically to treat infection and over 10 times above that to which it had been
exposed (25). Survivability of the adapted population in two other classes of antibiotic also
improved without the sample having ever been exposed to related substances indicating the
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development of cross-resistance. The MIC of tetracycline increased from 0.5 µg/mL to 16
µg/mL and that of amikacin increased from 0.5 µg/mL to 2 µg/mL (Table 1). There was a slight
increase in MIC for these two additional drugs in the untreated cohort of K. pneumoniae but that
increase does not compare to that of the adapted population. Current literature recommends a
treatment protocol for tetracycline that achieves a maximum antibiotic concentration level (Cmax)
of 2-5 µg/mL and a Cmax of 8-10 µg/mL of amikacin to prevent potential organ failure (31–33).
Based on this procedure, the adapted strain of K. pneumoniae developed in this study would be
clinically resistant to tetracycline.
Mutations Correlated to Increases in Resistance and Colony Size Variants
The primary aims of this study were to determine mutations unique to the 14-day adapted
population of K. pneumoniae 43816 which correlated to changes in resistance and to identify
mutations unique to the small and large colony variants within the 14-day adapted population.
DNA from samples of each treatment day during the adaptation phase of K. pneumoniae
indicated three mutations that chronologically align with increases in resistance to either
tetracycline or cephalothin. The three resistance-correlated mutations occurred in genes coding
for rpoB, TetR/AcrR transcriptional regulator, and wcaJ. The increases in resistance occurred in
a stepwise manner, similar to the increases in fitness observed in the E. coli long-term evolution
(LTEE) studies performed by Richard Lenski and reserachers investigating the populations
generated from the study (34–36). Further analyses, including cloning and ablation of genes of
interest, are needed to definitively state that the mutations identified in this study induced
increases in antibiotic resistance.
The location of the rpoB mutation was very close to a prior call in DNA recombination
protein RmuC in the sample sequenced using the SMRT cell method. The protein products of
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both genes interact closely with genomic DNA. RmuC is a regulator which can prevent sequence
inversion during replication (37). The gene has also been identified as possible multidrug
resistance (MDR) genes in other Gram-negative bacterial species (38, 39). However, rpoB is part
of the RNA polymerase protein complex and when mutated can inhibit the action of Rifampicin
in bacteria (40). In 1988, rpoB mutations were linked to rifamycin and Rifampin resistance in E.
coli (41, 42). Since that time, mutations in this gene which normally encodes a portion of the
RNA polymerase protein complex has been identified as a resistance gene in various classes of
bacteria (43). Additionally, the fact that the mutation in a gene tied to nucleic acid integrity
occurs first provides a possible mechanism for AR development which requires alterations in the
ability of the bacteria to maintain fidelity of its sequence. These mutations could increase the
occurrence of replication error mutations in progeny.
The AcrR subset of TetR regulators are one-component signal transduction systems
commonly associated with the transcription of efflux pumps in bacterial pathogens (44). TetR
regulators can also respond to a variety of ligands and effect different processes within the cell
(45). It is interesting that such a large insert would be found in a gene known for resistance to
tetracycline antibiotics when the adapted population of this study was exposed to a β-lactam.
Although the specific characteristics of this regulator is unknown, it could correspond with a
change in the presence of efflux pumps in the adapted population.
The position of the uncharacterized undecaprenyl phosphate-glucose phosphotransferase
in the SMRT sequencing report is close to the mutation found in wcaJ by Illumina sequencing so
they may be the same mutation (Table 4A, Table 5A). In Klebsiella pneumoniae, wcaJ is part of
the capsular cps operon and initiates production of colonic acid (46, 47). Absence of wcaJ has
been linked to increased resistance to phage treatment, decreased virulence in live murine
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models, and increased phagocytosis by macrophages (46). A separate study ablating the same
gene found that samples of Klebsiella pneumoniae creates a nonmucoid phenotype while
increasing biofilm production, altering cell shape, and increasing resistance to polymyxin (47).
The same work also confirmed that a lack of the wcaJ gene increased phagocytosis and lysis
inside of murine macrophages (47). Capsule in K. pneumoniae is a known resistance mechanism
and virulence factor so the mutation in wcaJ is notable. The present data indicate that the adapted
strain of bacteria have increased in mucoidy. Further experimentation would need to be done to
identify if this mutation or mutations in another capsular gene such as that identified in the sugar
ABC transporter ATP binding protein are responsible for the mucoid phenotype.
The LTEE study also provided estimates for the rapidity of fixation of mutations in a
constant environment. The population accumulated 20 mutations in the first 10,000 generations
of growth with a few rapid mutations that reached fixation in the population within 100
generations (35, 36). The three resistance-correlated mutations in the present study all fixed
within 360-378.9 generations. While the present study does use incremental changes in antibiotic
concentration, it does not counteract that these mutations were acquired rapidly and indicate a
fitness benefit to the adapted population. The speed with which these three mutations were
acquired also indicates that the sub-MIC concentration of cephalothin in the growth environment
did provide selective pressure. The sample from day one of antibiotic exposure identified
fixation of a mutation in rpoB. As this time point represents 24 hours of antibiotic treatment, the
mutation reached fixation within 36-37.9 generations using a generation time estimate from a
related K. pneumoniae strain of 38-40 minutes (48). After day one, the resistance of the adapted
population to tetracycline had the first jump from 1 µg/mL to 8 µg/mL. The rapidity of fixation
and correlated increase in survivability suggest that this mutation conferred a very high fitness
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advantage. It is possible that a necessary step in acquiring resistance for this population was the
mutation in a gene meant to monitor nucleic acid integrity and possibly allow for further changes
to the genome.
On day 6 a mutation in an uncharacterized TetR/AcrR family transcriptional regulator is
fixed, the same day that the first jump in survivability in cephalothin occurred (Figure 7). The
insert in this gene is first reported at a frequency of 25 % on day 1 of treatment. Given that the
average generation time for Klebsiella pneumoniae species ranges from 38-40 minutes and that a
marginal presence of the mutation on day 1 indicates the presence of the mutation at the
beginning of the experiment, this mutation becomes fixed in approximately 216-227.4
generations (48). While this is still a relatively fast acquisition, it is nowhere near as fast as the
mutation in rpoB. However, the increase in antibiotic survivability associated with the date this
mutation fixed was higher than that of rpoB (Fig 8). The TetR/AcrR mutation may be associated
with some other fitness cost that impeded fixation.
The third mutation correlated with an increase in antibiotic survivability was in the wcaJ
gene and appears as a fixed mutation on day 10. The MiGS data does not show any marginal call
of this mutation in prior samples and the percent of the population maintaining this mutation
dwindles thereafter to 64% in the 14-day whole group DNA sample. Since there was no prior
marginal call for the mutation, it is possible that it’s presence in the adapted population began
after sample collection on day 9. This would allow for 24 hours of growth to the fixation point
giving a fixation time of 36-37.9 generations. This mutation was associated with the highest
increase in antibiotic resistance (Fig 8). The increase in survivability coupled with the rapidity of
fixation indicate that this may be the most fit mutation of the three. A confounding factor to
consider is that the presence of the mutation in later sample days declines and this mutation is
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found to only be completely fixed after 14days in the small colony-forming variant. Future work
should assess if the fixation call was due to sampling error or an overabundance of small-colony
forming variant individuals at day 10.
The data collected also identified a unique genomic structure for the small and large
colony forming variants of the 14-day adapted population. Only 52% of large colony forming
subpopulation DNA contained the insert in TetR/AcrR family transcriptional regulator while the
insert was fixed throughout the small colony subpopulation. This mutation may be more
advantageous to the small colony variant population due to their smaller size. Additionally, the
deletion spanning between wcaJ and gndA only occurred in the small colony forming population.
As noted above, ablation of wcaJ in K. pneumoniae is linked to a decrease in species mucoidy
and antibiotic resistance. Similarly, gndA is a gene within the cps locus responsible for the K2
serotype and capsule formation of K. pneumoniae (49, 50). It seems likely that the enlarged
pellicle seen in the 14-day adapted population whole-group mixture is due to the large colony
variant only. Furthermore, the small colony subpopulation has a reduced resistance to
cephalothin compared to the large colony forming variant which has an intact wcaJ sequence.
The absence of the sequence differentially impacts resistance to a β-lactam which could be
explained by the two different classes of drugs. The prior study which ablated the capsule gene
wcaJ, tested resistance to polymyxin- a drug which acts by targeting LPS (47). Cephalothin
targets internal functions of gram-negative prokaryotes so the presence of a capsule barrier
would be beneficial. It could be that the small-colony forming subpopulation mutated
independently to rely more on the mutation in the TetR/AcrR regulator than capsule. Further
experimentation could focus on elucidating the downstream targets of this regulator to better
understand the resistance mechanism.
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Other Notable Mutations
Alterations in gene transcription between Klebsiella pneumoniae 43816 and the 14-day
adapted population also indicate three genes of interest. The potential function of TetR/AcrR
transcriptional regulator is discussed above. The increased transcription in the adapted
population could be due to a common signaling pathway used in response to stress caused by
tetracyclines in better understood organisms. Transcription of globin is decreased. Globins are
used to sequester and transport oxygen. These findings could suggest that the mutated population
has an altered metabolic profile which doesn’t require as much oxygen. Finally, the transcription
of deoxyribopyrimidine photolyase is also decreased. Ultraviolet radiation can create a distinct
form of DNA damage in the form of cyclobutene pyrimidine dimers which interfere with DNA
replication (51). Deoxyribopyrimidine photolyases can repair this damage and prevent potential
replication errors (52, 53). Reduced production of this gene removes another mechanism the cell
can prevent errors during DNA duplication. This may also serve the purpose of permitting more
mutations and more variation in the presence of antibiotic stress.
Assessing the adapted population’s survivability in amikacin came as a result of findings
in the first round of whole genome sequencing. In that report, a mutation was identified in an
uncharacterized n-acetyltransferase (NAT) coding region. In general, the different classes of
NATs act to transfer the acetyl group from acetyl-CoA to a target (54). Early identification of
this protein as a marker of resistance used the human genome. Human NATs, especially those
classified as arylamine NATs, are responsible for the effective activation of different antibiotics
(54). Arylamine NATs are also a known plasmid-mediated resistance gene in K. pneumoniae and
inhibit the effects of aminoglycoside class antibiotics (55, 56). This same subset of NATs have
been associated with bacterial resistance to antibiotics in other Gram negative bacteria (57). The
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mutated protein can prevent aminoglycosidic compounds from interacting with bacterial
lysosomes and prevent damage to the cell. The data in Table 4A shows a one nucleotide deletion
unique to the antibiotic resistant DNA sample in an N-acetyltransferase gene.
NATs have been identified throughout the genome of Klebsiella pneumoniae subspecies
acting as part of toxin-antitoxin systems, elements of transposons, or as arylamine NATs (58–
60). The data in Table 1 show an increase in resistance to amikacin, a commonly used
aminoglycoside, in both the untreated and adapted populations of Klebsiella pneumoniae 43816.
The increased MIC for the untreated population is minimal but the population exposed to
cephalothin for 14 days had an MIC four times higher than the parent strain. This data can
confirm that arylamine NAT-mediated resistance does not have to be transmitted on a plasmid.
In the present study, random mutation of the genomic region itself could have altered the protein
in a way that enhanced aminoglycoside tolerance.
Another gene of interest was the SGNH/GDSL hydrolase family protein. Initial sequence
results found 2 mutations in the coding region for this gene and one potential promoter mutation
in the adapted population (Figure 4A and 4B). The coverage of the coding region and promoter
mutations was near 50% and could be due to a distinction between the small and large colony
forming subpopulations in the 14-day treated sample. The SGNH superfamily derives its name
from a shared serine-glycine-asparagine-histidine amino acid sequence in which serine is
incorporated into the enzyme’s active site (61). The GDSL subfamily of the SGNH hydrolase
group is further specified by the inclusion of a glycine-aspartine-serine-leucine motif near the
active site (61). The SGNH protein family is a unique group with broad specificity and the
ability to cleave multiple esters and lipids (61). The active site of this enzyme can accept a range
of substrates and is known to undergo conformational changes based on available substrates (61).
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While this group has been extensively described in terms of structure and composition, much
work is yet to be done to determine in vivo functionality.
Comparing SMRT Cell and Illumina Sequencing Results
The sequence data obtained add to the growing set of literature regarding types of
genomic resistance genes, the effect of sub-MIC antibiotic exposure to mutation rates, and the
efficacy and sensitivity of different forms of whole genome sequencing. SMRT Cell sequencing
of the whole adapted population and untreated population of K. pneumoniae identified eight
nonsynonymous mutations in coding regions of seven genes and six potential promoter
mutations unique to the adapted population (Table 4A and B). A second round of Illumina
sequencing of the adapted whole-group identified only four unique mutations (Table 5A). Both
methods referenced the samples to the given NCBI sequence for Klebsiella pneumoniae 43816
(Reference number NZ_CP009208.1) but the sequencing and statistical methodology differed.
Illumina sequencing is a high-throughput method which sequences amplified DNA fragments
(62). The method is known to be fast and inexpensive, which proved to be true in the present
study as well (62). Illumina’s low error rate has allowed it to be used successfully identify
single-nucleotide polymorphisms in an effort to track pathogenic outbreaks (62). SMRT cell
sequencing is a long-read sequencing technique which involves circularizing sample DNA with a
hairpin structure that is loaded into a cell that houses a stationary DNA polymerase (62, 63).
Even though larger segments of DNA can be processed at one time, the potential for error in a
single read can be as high as 14% requiring the use of multiple reads to validate base calls (62).
It is a more expensive sequencing option but has the benefit of avoiding amplification bias in
base calls as amplification isn’t necessary for the process, it can handle many of the genomic
structures common to AR elements like transposons and extended repeats, and is preferred for de
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novo sequencing of new references (62–64). Recent work has suggested that both long-read
methods, like SMRT cell sequencing, and short-read methods, like Illumina sequencing, be
combined for a hybrid approach for the most accurate formation of novel sequences especially
those of the Enterobacteriaceae family (64). The data from both rounds of sequencing found that
the SMRT cell method identified more polymorphisms in the adapted population genome and
was able to identify mutations in noncoding regions unlike the Illumina method. Additionally,
the evolution of a resistant phenotype can require cooperative mutations adding difficulty to the
present study’s ability to directly trace the effects of one mutation to a quantifiable change in
antibiotic survival (65). Both the SMRT cell and Illumina sequence methods should be used on
all of the DNA samples to create a better library of potential mutations.
Both sequencing methods noted mutations in genes related to signal transduction,
regulation of transcription, DNA integrity, and capsule formation. The mutations identified do
not all match between both sequencing methods, nor are the calls for similar genes found in the
exact same position or using the same base changes (Table 4 A and B, Table 5 A-C). This could
reflect differences in methodology, genome construction in the two methods, and/or inherent
error. However, it is more likely that the inconsistencies in the two sequencing methods results
from the sample of DNA provided for analysis. The frozen stocks created of the adapted K.
pneumoniae and the frozen stocks for each treatment day consisted of a subset of a population of
bacteria that were grown in a stress condition. A sample of that stock was then regrown and
allowed to proliferate then lysed to generate DNA for analysis. The process of sampling and
growing from a heterogenous population allows for a degree of variance in the individual
bacterium that make up the sample population. Regardless of methodology, each report showed a
wide range in affected gene function, many of which are not classically considered AR genes in
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Klebsiella pneumoniae. The results from both forms of sequencing were absent of known βlactamase genes and penicillin binding proteins. The adapted population of K. pneumoniae
generated by long-term antibiotic exposure did not have evidence of one of the most common
bacterial β-lactam defense mechanisms. Any genetic analysis other than a whole-sequence
format would likely have found no mutations limiting the ability to gain insight into how
antibiotic exposure influences genetic evolution.
Mutation Number, Rate, and Genetic Heterogeneity
The selection window hypothesis holds that sub-MIC level antibiotic exposure should
generally increase bacterial mutation rates (12, 13). The idea is that higher mutation rates
improve the chances of generating an adaptive genetic change that will help the organisms
survive antibiotic stress. Methodologies employed by studies testing this theory have generally
identified “mutants” by plating samples of a bacteria exposed to an antibiotic on media
inoculated with some other antibiotic substance (8, 20). The number of successful colonies
grown is compared to that of a sample placed on an un-inoculated media (8, 20). In these cases,
the mutation rate reported is better understood as “the in vitro frequency at which detectable
mutants arise” (65). Regardless, mutation rate analyses using that methodology tend to indicate
that at lower antibiotic concentrations the mutation rate is high and this rate declines as the
concentration of antibiotic nears the MIC (20, 65). Contrastingly, when whole-genome analysis
is incorporated along with mutation accumulation analysis, substitutions and insertions/deletions
increased in frequency as exposure to norfloxacin increased in E.coli (66). Additionally, the rate
of mutation in known resistance genes was tracked in P. aeruginosa isolates exposed to
antibiotics and generated conflicting results (22).
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The present study utilized whole genome sequencing to identify mutations across the
entire K. pneumoniae genome for the antibiotic-treated and unexposed sample after 14 days of
total treatment. The data from SMRT cell sequencing shows a higher number of mutations in the
untreated sample compared to the adapted cohort. It is interesting to note that the number of
genetic changes at fixation and below that level outnumber the adapted population. As noted by
Long et. al., a true mutation accumulation analysis which could be interpreted as a frequency of
genetic polymorphism per generation would require repeatedly passing a bacteria through
bottlenecks to mitigate any selective influences (66). The fact that the adapted population in this
study was maintained as a whole group when subcultured may affect the relative number of
mutations identified by whole genome sequencing. Another factor at work is that the treatment
concentration of cephalothin did surpass the initial MIC of K. pneumoniae 43816 for over half of
the adaptation period (Table 1). Both the selection window hypothesis and adaptive studies of
bacterial mutation would suggest that such a high concentration would decrease mutation rates
compared to an unexposed cohort and explain the low number of identified polymorphisms (8,
12, 13, 20, 65).
The depth of coverage results from both rounds of sequencing also indicate a certain level
of genetic heterogeneity in the adapted population of K. pneumoniae. Many genes can generate
the phenotype of antibiotic resistance therefore the individual genotypes from resistant samples
are not always identical (65). The presence of unfixed mutations among the adapted population
in genes such as the SGNH/GDSL hydrolase protein, wcaJ, and gndA in the whole group
analyses and TetR/AcrR transcriptional regulator in the large colony-forming variant are
understandable. Functional investigations of these genes in K. pneumoniae would better
elucidate how or if these mutations affect the organism’s survival in antibiotic.
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Conclusions
The present study confirms findings in other pathogens regarding low level antibiotic
exposure over time. The adapted K. pneumoniae population showed that sub-MIC exposure can
generate to cross-resistance. The adapted population here developed an increased resistance to
drugs in two different antibiotic classes after treatment. The phenotypic findings correlate to
identified mutations in known resistance genes for other bacteria- n-acetyltransferase and
TetR/AcrR transcriptional regulator.
Secondly, the development of resistance by the adapted population in this model confirm
findings that K. pneumoniae has resistance genes inherent to its own genome and doesn’t require
acquisition of foreign DNA to develop an AR phenotype (18). The treatment methodology did
not expose either the untreated or treated populations to genetic material from an outside source.
The populations were subcultured separately and any mutations that arose, fixed or not, had to
have been developed in the DNA replication process. This highlights the need to better
understand bacterial pathogen genomes to better predict, prevent, and treat resistant forms.
Finally, two mutations can be correlated to recorded increases in MIC for the adapted
strain- rpoB on day 6, and wcaJ on day 10 of treatment. While wcaJ is a known virulence factor
and resistance gene for K. pneumoniae, rpoB is not. This mutation also became fixed on a day
with the largest increase in MIC. Without sequencing the whole-genome of these samples, it is
very likely that the mutation would have been overlooked. The majority of antibiotic adaptation
analyses focus on known or suspected AR genes. The present data indicate that a more thorough
query into all genes and potential promoters could shed more light into how antibiotic adaptation
occurs.
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Tables and Figures
Figure 1: Bacterial growth rates as a function of antibiotic exposure from Gullberg et. al. 2011.
A) red line represents resistant strain and the blue line represents the susceptible strain. The
green zone is the range of antibiotic concentrations below the selection window, orange and red
zones are mutant selective. B) Relative exponential growth rates for susceptible (open circle) and
resistant (closed circle) strains.
Figure 2: Experimental Design used to develop antibiotic resistant population of K. pneumoniae
43816
Figure 3: Growth of ATCC 43816, sample subcultured for 14 days without antibiotic, and
sample exposed to Cephalothin for 14 days.
Figure 4: Aqueous culture with capsule from 3 samples of K. pneumoniae 43816. Sample titled
Klebsiella pneumoniae 43816 uses the laboratory isolate, sample titled untreated is from the
population of ATCC 43816 serially passaged without antibiotic and the sample on the right was
treated with Cephalothin for 14 days.
Figure 5: Diluted plate sample of adapted K. Pneumoniae 43816 with large and small colony
variants demarcated.
Figure 6: Enlarged gram stain of adapted K.pneumoniae 43816 cultures. The image is on the left
is from the large colony variant and the image on the right is from the small colony variant.
Figure 7: Graph of MIC50 breakpoints for the adapted strain in response to Cephalothin
treatment. Data for Cephalothin MIC50 is represented by the blue line and data for Tetracycline
MIC50 is represented by the orange line. Each dot on the map denotes a sample from one
treatment day.
Figure 8: Graph of MIC50 breakpoints for the adapted strain in response to Cephalothin
treatment with fixed mutations noted. Data for Cephalothin MIC50 is represented by the blue
line and data for Tetracycline MIC50 is represented by the orange line. Mutations fixed in the
adapted strain are marked by day of fixation.
Figure 9: Transcriptional expression of genes with mutated coding regions assessed by qPCR
and analyzed using the ΔΔCt method. Genes are normalized to gapA and extracts from the
treated population (14T) are compared to lab strain K. pneumoniae 43816 (Day 0) *p<0.01
Figure 10: Transcriptional expression of genes with mutated promotor regions assessed by
qPCR and analyzed using the ΔΔCt method. Genes are normalized to gapA and extracts from the
treated population (14T) are compared to lab strain K. pneumoniae 43816 (Day 0) *p<0.01
Table 1: Minimum inhibitory concentrations calculated for untreated culture grown for 14 days
and culture treated with low-level antibiotic for 14 days. Concentration determined from average
of 3 data points for each culture. * p<0.05; ** p<0.0005
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Table 2: Minimum inhibitory concentrations to Cephalothin for adapted population colony size
variants. Concentration determined from average of 3 data points for each culture.
Table 3: List of primers used for qPCR.
Table 4: List of identified nucleotide changes for AR K. pneumoniae 43816 culture using SMRT
Cell sequencing. These changes are not found in the susceptible counterpart. A contains unique
changes in protein coding regions, B contains the unique changes in potential promoter regions.
Table 5: List of identified nucleotide changes for AR K. pneumoniae 43816 culture using MiGS
Illumina sequencing. These changes are not found in the susceptible counterpart. A contains
unique changes in protein coding regions, B lists mutations identified in the large colony forming
variant of the adapted population, and C lists the mutations identified in the small colony
forming variant of the adapted population.
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Figure 8:
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Figure 9
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Figure 10

Relative Transcription of Genes with Mutated Promotors
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Table 1:
50% Minimum Inhibitory Concentration (MIC50) of Antibiotic
Antibiotic

K. pneumoniae 43816

Day 14 Untreated

Day 14 Treated

Tetracycline

0.5 µg/mL

1 µg/mL*

16 µg/mL**

Cephalothin

4 µg/mL

4 µg/mL

125 µg/mL**

Amikacin

0.5 µg/mL

1 µg/mL*

2 µg/mL**
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Table 2:

Minimum Inhibitory Concentration of Cephalothin
MIC 50

Breakpoint

Large Colony Variant

500 µg/mL

>500 µg/mL

Small Colony Variant

125 µg/mL

500 µg/mL
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Table 3: qPCR Primers

Gene
SGNH/GDSL hydrolase family protein
N-acetyltransferase
globin
TetR/R family transcriptional regulator
sugar ABC transporter ATP-binding protein
DNA recombination protein RmuC
undecaprenyl-phosphate glucose
phosphotransferase
Peptide Chain Release Factor 3
LysR Family Transcriptional Regulator
Type II Aspariginase
Deoxyribodipyrimidine Photo-Lyase
Cyclic Di-GMP Phosphodiesterase

Forward Primer
GGAGCTATCCGGTTTAGCTATTT
CCCAGGTTCATTATCGGTGTATC
CGCTGTGCGATGAAGAGAT
GCTCGTCCAAAGAGTGAAGATA
GGTCGGCTCATCGAGAATTAAG
GTCGGGCTAACCAGCATAAT

Reverse Primer
GACAGCAACGTCGCCTATAA
GGCTTAACCACTGGGAGAATTA
TGACCTGCGGTCTGATAGT
GTGGCGAAATAGCGAAACAG
CGCCGACGATGGATCAAATTA
GTGCTGATGTTTATTCCCGTTG

GTGCTGGCTTTGTTGTTACTC
CGGTCTGATACAGGTAGGTTTC
CGGCATCCCTACCTTGAAC
CGGTTCCGGCGTAGATAATAC
GGCGTTCATTGAATTCGTACTG
TGATCGTCAGCACGTAATAGC

CAAACTGATTCCTGCTGGTAAAG
TGCTGGATGAAGTCGAGAAC
GCCGGTATTATGAGGAGTGTAAA
CTGCCGAAGGTGGTGATT
TACCGCTGTGGGTAGAAGA
CCGCTGAAGGTCTATCTGTATG
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Table 4:
A.
Adapted Population Coding Region Changes
Position Original New
Coverage
Gene Changed
10279
10285
412527
1125537

G
G
G
.

2008934 .
2063994 C
3225592 C

C
C
Deletion
Insert T
Insert
TTTCGCTA
Deletion
Deletion

5188116 T

G

43
43
100
100
100
100
100
100

SGNH/GDSL hydrolase family protein
SGNH/GDSL hydrolase family protein
N-acetyltransferase
globin
TetR/AcrR family transcriptional regulator
sugar ABC transporter ATP-binding protein;
DNA recombination protein RmuC
undecaprenyl-phosphate glucose
phosphotransferase

B.
Adapted Population Promoter Changes
Coverage
Position Original New
Gene Changed
10412
2657272
1078904
1294495
1823692
5050494

T
G
C
G
.
.

Deletion
Deletion
Deletion
Deletion
Insert A
Insert A

56
100
100
100
100
100

2 bases before reading frame for SGNH hydrolase
78 bases before peptide chain release factor 3
11 before LysR family transcriptional regulator
81 bases before type II aspariginase
127 before deoxyribodipyrimidine photo-lyase
111 before cyclic di-GMP phosphodiesterase
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Table 5:
A.
Position

Original

2,008,948 .

MiGS Identified Adapted Population Changes
Coverage Gene Changed
New
Insert
TATTTCGC

100
100

3,191,984 A

T
64

5,187,772 T

G
64

5,189,876 unspecified unspecified

TetR/AcrR family transcriptional regulator
rpoB/DNA-directed RNA polymerase subunit
beta
wcaJ/undecaprenyl phosphate-glucose
phosphotransferase
gndA/NADP-dependent phosphogluconate
dehydrogenase

B.
Position

Original

Large Colony Adapted Population Changes
Coverage Gene Changed
New

100
3,191,984 A
T
1,548,640 unspecified unspecified 15
Insert
52
2,008,948 .
TATTTCGC

rpoB/DA-directed RNA polymerase subunit beta
ComEC family protein
TetR/AcrR family transcriptional regulator

C.

Position

Original

2,008,948 .

Small Colony Adapted Population Changes
Coverage Gene Changed
New
Insert
TATTTCGC

100
100

3,191,984 A
T
4,676,685 T
G
5,187,773 Deletion of 2,103 bp

100
100

TetR/AcrR family transcriptional regulator
rpoB/DA-directed RNA polymerase subunit
beta
YfiR family protein
wcaJ and gndA
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